Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Avg. shares outstanding Weighted Average Number of Shares Outstanding, Diluted [Abstract] Trading Arrangement: Trading Arrangement [Axis] Maximum Maximum [Member] Separation Related Costs Separation Related Costs [Member] Separation Related Costs Portion at Fair Value Measurement Portion at Fair Value Measurement [Member] Statistical Measurement [Domain] Statistical Measurement [Domain] Short-term Debt, Type [Axis] Short-Term Debt, Type [Axis] Title of 12(b) Security Title of 12(b) Security Carrying Amount Reported Value Measurement [Member] Document Fiscal Year Focus Document Fiscal Year Focus Acquisition related costs Business Combination, Acquisition-Related Cost, Expense Credit Support Agreement (CSA) Derivative Liability, Subject to Master Netting Arrangement, Asset Offset Derivative Instruments, Gain (Loss) [Table] Derivative Instruments, Gain (Loss) [Table] Weighted average interest rate Debt, Weighted Average Interest Rate Adjustment to Compensation, Amount Adjustment to Compensation Amount Changes in estimated fair value(6) Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Change In Estimated Fair Value Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Change In Estimated Fair Value Financial Instrument [Axis] Financial Instrument [Axis] Segment Reporting [Abstract] Segment Reporting [Abstract] DARZALEX DARZALEX [Member] DARZALEX [Member] Restructuring Plan [Axis] Restructuring Plan [Axis] Common stock — par value $1.00 per share (authorized 4,320,000,000 shares; issued 3,119,843,000 shares) Common Stock, Value, Issued Accrued compensation and employee related obligations Employee-related Liabilities, Current Trademarks Trademarks [Member] 1.150% Notes Due November 2028 1.150% Notes Due November 2028 [Member] 1.150% Notes Due November 2028 ADVANCED ADVANCED [Member] ADVANCED [Member] Pensions and other benefit plans Retirement Benefits [Text Block] Loss contingency accrual Loss Contingency Accrual Integration-related cost, expense Business Combination, Integration-Related Cost, Expense Restatement Determination Date Restatement Determination Date Sales of investments Proceeds from Sale, Maturity and Collection of Investments Expected return on plan assets Defined Benefit Plan, Expected Return (Loss) on Plan Assets Employee related obligations (Note 6) Employee-related Liabilities Derivative Instrument [Axis] Derivative Instrument [Axis] Intangible assets with indefinite lives: Intangible Asset, Excluding Goodwill, Indefinite-Lived [Abstract] U.S. Gov’t securities US Treasury and Government [Member] Proceeds from the disposal of assets/businesses, net (Note 10) Proceeds from Sale of Productive Assets Goodwill, related to divestitures Goodwill, Divestiture Amendment Flag Amendment Flag Goodwill [Line Items] Goodwill [Line Items] Current liabilities: Liabilities, Current [Abstract] Credit losses and accounts receivable allowances Accounts Receivable, Credit Loss Expense (Reversal) 3.75% Notes due 2047 3.75% Notes due 2047 [Member] 3.75% Notes due 2047 [Member] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Disposal Group Classification [Axis] Disposal Group Classification [Axis] CONTACT LENSES / OTHER CONTACT LENSES/OTHER [Member] CONTACT LENSES/OTHER [Member] Orthopaedics Business Orthopaedics Business [Member] Orthopaedics Business Halda Therapeutics Halda Therapeutics [Member] Halda Therapeutics Schedule of Available for Sale Securities Maturities Debt Securities, Available-for-Sale [Table Text Block] Product Liability Contingencies [Table] Loss Contingencies [Table] Less: shares which could be repurchased under treasury stock method Shares Which Could Be Repurchased Under Treasury Stock Method Common stock assumed to be purchased using the proceeds that could be obtained upon exercise of potential shares exercisable under stock option plans, at the average market price during the period. Investments [Domain] Investments [Domain] Amortization Amortization Other comprehensive income (loss), net of tax Other Comprehensive Income (Loss), Net of Tax [Abstract] HIPS HIPS [Member] HIPS [Member] Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Entity Address, State or Province Entity Address, State or Province Number of plaintiffs Loss Contingency, Number of Plaintiffs Other Cardiovascular Other Cardiovascular [Member] Other Cardiovascular 1.650% Notes Due May 2035 1.650% Notes due 2035 (1.5B Euro 1.1354) 1.650% Notes Due 2035 [Member] 1.650% Notes Due 2035 [Member] PEO Total Compensation Amount PEO Total Compensation Amount Common stock, par value per share (in usd per share) Common Stock, Par or Stated Value Per Share Additions to Property, Plant & Equipment Segment Reporting, Long-Lived Asset, Expenditure for Addition Intangible assets, net (Note 3) Total intangible assets — net Intangible Asset, Excluding Goodwill, after Accumulated Amortization Income Tax Contingency Income Tax Contingency [Line Items] Derivative, notional amount Derivative, Notional Amount Basic (shares) Average shares outstanding — basic Weighted Average Number of Shares Outstanding, Basic Credit support agreements activity, net Proceeds (Payments) from (to) Credit Support Agreements, Investing Activities Proceeds (Payments) from (to) Credit Support Agreements, Investing Activities Retirement Benefits [Abstract] Retirement Benefits [Abstract] Equity Investment [Roll Forward] Equity Investment [Roll Forward] Equity Investment [Roll Forward] Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount Fair Value, by Balance Sheet Grouping [Table] Fair Value, by Balance Sheet Grouping [Table] OTHER NEUROSCIENCE OTHER NEUROSCIENCE [Member] OTHER NEUROSCIENCE [Member] Loss Contingencies [Line Items] Loss Contingencies [Line Items] Number of reportable segments Number of Reportable Segments Total current liabilities Liabilities, Current Goods in process Inventory, Work in Process, Net of Reserves 3.55% Notes Due 2044 (1.0B Euro 1.0721) 3.55% Notes Due 2044 (1.0B Euro 1.0721) [Member] 3.55% Notes Due 2044 (1.0B Euro 1.0721) Due after five years through ten years Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10 Short-term Debt, Type [Domain] Short-Term Debt, Type [Domain] Entity Address, City or Town Entity Address, City or Town 6.95% Notes due 2029 6.95% Notes due 2029 [Member] 6.95% Notes due 2029 [Member] Cost Basis Debt Securities, Available-for-Sale, Amortized Cost, Fiscal Year Maturity [Abstract] Defined Benefit Plan Disclosure [Line Items] Defined Benefit Plan Disclosure [Line Items] ABIOMED Abiomed [Member] Abiomed Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Excess of carrying value over fair value of debt Excess Of Carrying Value Over Fair Value Of Debt Excess Of Carrying Value Over Fair Value Of Debt Foreign Plan Foreign Plan [Member] Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Class of Stock [Axis] Class of Stock [Axis] Equity Investments with readily determinable value Equity Investments with Readily Determinable Value [Member] Equity Investments with Readily Determinable Value [Member] Finite-lived intangible assets, net Intangible Asset, Finite-Lived, after Accumulated Amortization Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Western Hemisphere, excluding U.S. Western Hemisphere, excluding U.S. [Member] Western Hemisphere, excluding U.S. [Member] Dividends to shareholders Payments of Ordinary Dividends U.S. reverse repurchase agreements Securities Loaned or Sold under Agreements to Repurchase [Member] Significant other observable inputs Level 2 Fair Value, Inputs, Level 2 [Member] Less accumulated amortization Intangible Asset, Finite-Lived, Accumulated Amortization Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Other comprehensive income (loss) Other comprehensive income (loss), net of tax Change from continuing operations Other Comprehensive Income (Loss), Net of Tax Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Interest income percent to sales Investment Income Interest Percent To Sales Investment income interest percent to sales. U.S. United States UNITED STATES Effect of Change in Accounting Estimate, Type [Domain] Effect of Change in Accounting Estimate, Type [Domain] Net change Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax Other (income) expense, net percent to sales Other Non Operating Income Expense Percent To Sales Other non operating income expense percent to sales. 3.35% Notes Due 2036 (800MM Euro 1.0721) 3.35% Notes Due 2036 (800MM Euro 1.0721) [Member] 3.35% Notes Due 2036 (800MM Euro 1.0721) New and Recently Adopted Accounting Standards New Accounting Pronouncements, Policy [Policy Text Block] Litigation Case Litigation Case [Axis] Operating Profit by Segment of Business Segment Reporting [Table Text Block] Domestic Plan Domestic Plan [Member] Employee benefit plans income (loss) Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, Tax RYBREVANT + LAZCLUZE RYBREVANT + LAZCLUZE [Member] RYBREVANT + LAZCLUZE Due after one year through five years Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five Document Period End Date Document Period End Date Changes in assets and liabilities, net of effects from acquisitions and divestitures: Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract] Net cash used for investing activities Cash Provided by (Used in) Investing Activity, Including Discontinued Operation Equity Awards Adjustments, Excluding Value Reported in Compensation Table Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member] Unrecognized tax benefits Unrecognized Tax Benefits Debt instrument, face amount Debt Instrument, Face Amount Restructuring charges recorded to date Restructuring and Related Cost, Cost Incurred to Date Security Exchange Name Security Exchange Name Term Debt Instrument, Term Less: common stock held in treasury, at cost (711,615,000 and 711,904,000 shares) Treasury Stock, Common, Value 0.95% Notes due 2027 0.95% Notes due 2027 [Member] 0.95% Notes due 2027 PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA [Member] PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA [Member] In-process research and development percent to sales Research and development in process percent to sales research and development in process percent to sales Firefly Bio, Inc. Firefly Bio, Inc. [Member] Firefly Bio, Inc. Accumulated other comprehensive income (loss) (Note 7) Accumulated Other Comprehensive Income (Loss), Net of Tax Entity Shell Company Entity Shell Company Consolidation Items [Domain] Consolidation Items [Domain] Contribution to pension plans Payment for Pension Benefits Cash and Cash Equivalents [Line Items] Cash and Cash Equivalents [Line Items] 4.375% Notes due 2033 4.375% Notes due 2033 [Member] 4.375% Notes due 2033 [Member] Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] Earnings per share Earnings Per Share [Text Block] Name Outstanding Recovery, Individual Name Accumulated other comprehensive loss on derivatives, after tax AOCI, Cash Flow Hedge, Cumulative Gain (Loss), after Tax NET EARNINGS PER SHARE Earnings Per Share [Abstract] Earnings Per Share [Abstract] Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Document Fiscal Period Focus Document Fiscal Period Focus Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Other Investment Not Readily Marketable [Table] Other Investment Not Readily Marketable [Table] Total liabilities Liabilities Trading Symbol Trading Symbol Geographical [Domain] Geographical [Domain] Total intangible assets with indefinite lives Intangible Asset, Excluding Goodwill, Indefinite-Lived Additions to property, plant and equipment Payments to Acquire Property, Plant, and Equipment Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member] Pension Adjustments Prior Service Cost Pension Adjustments Prior Service Cost [Member] Accrued taxes on income (Note 5) Accrued Income Taxes, Current Company Selected Measure Name Company Selected Measure Name Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Net change OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax Employee Benefit Plans Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member] 1.30% Notes due 2030 1.300% Notes due 2030 [Member] 1.300% Notes due 2030 Schedule of Effect of Derivatives not Designated as Hedging Instruments Derivatives Not Designated as Hedging Instruments [Table Text Block] Asset Class [Domain] Asset Class [Domain] Marketable Securities Cash, Cash Equivalent, and Investment [Table Text Block] CASH FLOWS FROM OPERATING ACTIVITIES Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract] Earnings before provision for taxes on income percent to sales Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Percent To Sales Income loss from continuing operations before income taxes minority interest and income loss from equity method investments percent to sales. Compensation Amount Outstanding Recovery Compensation Amount Individual: Individual [Axis] Net loss/(gain) on sale of assets/businesses Gain (Loss) on Sale of Assets and Asset Impairment Charges Diluted (shares) Average shares outstanding — diluted Weighted Average Number of Shares Outstanding, Diluted Cash dividends paid (in dollars per share) Common Stock, Dividends, Per Share, Cash Paid Cross currency interest rate swaps Cross Currency Interest Rate Contract Cross Currency Interest Rate Contract [Member] Entity Emerging Growth Company Entity Emerging Growth Company Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Cardiovascular / Metabolism / Other Cardiovascular/Metabolism/Other [Member] Cardiovascular/Metabolism/Other [Member] Disposal Group Name [Domain] Disposal Group Name [Domain] Underlying Security Market Price Change Underlying Security Market Price Change, Percent Commercial Paper Commercial Paper [Member] Entities [Table] Entities [Table] Prior service cost amortization during period Other Comprehensive (Income) Loss, Pension and Other Postretirement Benefit Plans, Net Prior Service Cost (Credit), Net of Amortization, Arising During Period, Net of Tax Other Comprehensive (Income) Loss, Pension and Other Postretirement Benefit Plans, Net Prior Service Cost (Credit), Net of Amortization, Arising During Period, Net of Tax Legal Proceeding (Textuals) Legal Proceeding (Textuals) [Abstract] Legal Proceeding Textuals Abstract. INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA INVEGA SUSTENNA/XEPLION/TRINZA/TREVICTA [Member] INVEGA SUSTENNA/XEPLION/TRINZA/TREVICTA [Member] Loans and notes payable Current Debt Short-Term Debt Accrued rebates, returns and promotions Accrued Rebates Returns And Promotions Reflects the estimated obligations due within one year for rebates, returns and promotions. Reserves include such items related to Medicaid rebates, product returns due to expiration, product recalls, current portion of coupons and volume-based sales incentives programs. Carrying Amount of the Hedged Liability Total Gross Liabilities Derivative Liability, Subject to Master Netting Arrangement, before Offset Purchased In-Process Research And Development Purchased In-Process Research And Development [Member] Purchased In-Process Research And Development [Member] Gross profit Gross Profit Customer relationships and other intangible assets Other Intangible Assets [Member] Derivatives not designated as hedging instruments : Assets Foreign Currency Derivative Instruments Not Designated as Hedging Instruments, Asset at Fair Value Financial assets and liabilities at fair value Derivative Instrument Detail [Abstract] Award Timing Predetermined Award Timing Predetermined [Flag] Treasury Stock Amount Treasury Stock, Common [Member] Intangible Asset, Goodwill and Other [Abstract] Intangible Asset, Goodwill and Other [Abstract] 3.700% Notes Due February 2055 3.700% Notes Due February 2055 [Member] 3.700% Notes Due February 2055 Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Fair Value, Inputs, Level 1 [Member] Quoted prices in active markets for identical assets and liabilities Level 1 Fair Value, Inputs, Level 1 [Member] 4.50% Notes due 2040 4.50% Debentures due 2040 [Member] 4.50% Debentures due 2040 [Member] Worldwide effective income tax rate (as a percent) Effective Income Tax Rate Reconciliation, Percent Talc Talc [Member] Talc [Member] Orthopaedics Restructuring Plan Orthopaedics Restructuring Plan [Member] Orthopaedics Restructuring Plan Indefinite-lived Intangible Assets, Major Class Name [Domain] Intangible Asset, Indefinite-Lived, Class [Domain] Adjustments To Revenue Recognized, Percent Adjustments To Revenue Recognized, Percent Adjustments To Revenue Recognized, Percent Potential shares exercisable under stock option plans Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements Debt Securities, Available-for-sale [Abstract] Debt Securities, Available-for-Sale [Abstract] 5.85% Notes due 2038 5.85% Debentures due 2038 [Member] 5.85% Debentures due 2038 [Member] All Executive Categories All Executive Categories [Member] 3.20% Notes Due November 2032 3.20% Notes Due June 2032 [Member] 3.20% Notes Due June 2032 SIMPONI / SIMPONI ARIA Simponi/Simponi Aria [Member] Simponi/Simponi Aria [Member] Pension Adjustments Service Cost Pension Adjustments Service Cost [Member] Components of Net Periodic Benefit Cost Schedule of Net Benefit Costs [Table Text Block] Scenario [Domain] Scenario [Domain] Total debt securities Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Amortized Cost XARELTO Xarelto [Member] Xarelto [Member] Milestone payments receivable Other Commitment, Milestone Payments Receivable Other Commitment, Milestone Payments Receivable CAPLYTA CAPLYTA [Member] CAPLYTA Shockwave Shockwave [Member] Shockwave AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward] AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward] Due within one year Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One Reconciliation of Basic Net Earnings per Share to Diluted Net Earnings per Share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Long-term Debt, Type Debt Instrument, Name [Domain] Segments of business and geographic areas Segment Reporting [Text Block] Minimum Minimum [Member] 4.80% Notes due 2029 4.80% Notes Due 2029 [Member] 4.80% Notes Due 2029 Investment Type [Axis] Investment Type [Axis] Expiration Date Trading Arrangement Expiration Date 4.50% Notes due 2043 4.50% Notes due 2043 [Member] 4.50% Notes due 2043 [Member] Hedging Relationship [Axis] Hedging Relationship [Axis] Provision for taxes on income percent to sales Income Tax Expense Benefit Percent To Sales Income tax expense benefit percent to sales. Intangible Asset Amortization Expense Intangible Asset, Finite-Lived, Amortization Expense [Table Text Block] Effect of exchange rate changes on cash and cash equivalents Effect of Exchange Rate on Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing Derivative, Excluded Component, Gain (Loss), Recognized in Earnings Income Statement Location [Axis] Location, Statement of Income, Balance [Axis] Sales to customers percent to sales Sales Revenue Goods Net Percent To Sales Sales revenue goods net percentage to sales. Currency translation/Other Goodwill, Other Increase (Decrease) Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Total shareholders’ equity Beginning balance Ending balance Equity, Including Portion Attributable to Noncontrolling Interest Non-U.S. sovereign securities Sovereign Debt Securities [Member] Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member] Sales/ Purchases/Other Equity Investments, Increase (Decrease) from Acquisition (Sale) During Period Equity Investments, Increase (Decrease) from Acquisition (Sale) During Period Business Combination [Line Items] Business Combination [Line Items] Net periodic benefit cost/(credit) Defined Benefit Plan, Net Periodic Benefit Cost (Credit) Aggregate Pension Adjustments Service Cost Aggregate Pension Adjustments Service Cost [Member] Derivative [Table] Derivative [Table] Common stock, shares authorized (in shares) Common Stock, Shares Authorized Reconciliation of basic net earnings per share to diluted net earnings per share Earnings Per Share Reconciliation [Abstract] Useful life (in years) Intangible Asset, Finite-Lived, Useful Life 3.600% Notes Due February 2045 3.600% Notes Due February 2045 [Member] 3.600% Notes Due February 2045 Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] Intra-Cellular Therapies, Inc. Intra-Cellular Therapies, Inc. [Member] Intra-Cellular Therapies, Inc. Intangible Assets and Goodwill Schedule of Finite and Indefinite-Lived Intangible Assets Excluding Goodwill by Major Class [Table Text Block] Schedule of Finite and Indefinite-Lived Intangible Assets Excluding Goodwill by Major Class [Table Text Block] Exercise Price Award Exercise Price Schedule of Restructuring and Related Costs [Table] Restructuring Cost [Table] Cash flows used for investing activities Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract] Segment Reporting [Line Items] Segment Reporting [Line Items] Document Quarterly Report Document Quarterly Report Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member] Segments [Domain] Segments [Domain] Segments [Domain] Europe Europe [Member] Interest Rate Swap Interest Rate Swap [Member] Equity Investments without readily determinable value Equity Investments without Readily Determinable Value [Member] Equity Investments without Readily Determinable Value [Member] Scenario [Axis] Scenario [Axis] Disposal Group Classification [Domain] Disposal Group Classification [Domain] Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Assets acquired including goodwill Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets Acquired Including Goodwill Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets Acquired Including Goodwill Business Combination [Table] Business Combination [Table] 4.55% Notes Due 2029 4.55% Notes Due 2029 [Member] 4.55% Notes Due 2029 Acquisitions, divestitures and other arrangements Mergers, Acquisitions and Dispositions Disclosures [Text Block] Equity Component [Domain] Equity Component [Domain] PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Forward foreign exchange contracts Foreign Exchange Contract [Member] Adoption Date Trading Arrangement Adoption Date Percent Change Percentage Change In Sales By Geographic Area Percentage change in sales by geographic area. Surgery Surgery [Member] Surgery [Member] Stated interest rate (as a percent) Debt Instrument, Interest Rate, Stated Percentage Cash dividends paid Dividends, Common Stock, Cash Total shareholders’ equity Equity, Attributable to Parent Remicade Remicade [Member] Remicade [Member] Restructuring Type [Axis] Restructuring Type [Axis] Available-for-sale Securities, Equity Securities Equity Securities, FV-NI, Current Business combination, other asset Business Combination, Recognized Asset Acquired, Other Asset Business Combination, Recognized Asset Acquired, Other Asset Tremfya Tremfya [Member] Tremfaya Assets Assets [Abstract] 5.25% Notes due 2054 5.25% Notes Due 2054 [Member] 5.25% Notes Due 2054 Title Trading Arrangement, Individual Title Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Available-for-sale Securities - Carrying Amount Debt Securities, Available-for-Sale, Amortized Cost Accounting Policies [Abstract] Accounting Policies [Abstract] Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Amount of gain or (loss) reclassified from AOCI into income Derivative Instruments, Gain (Loss) Reclassification from Accumulated OCI to Income, Estimated Net Amount to be Transferred Insider Trading Policies and Procedures [Line Items] Neuroscience Neuroscience [Member] Neuroscience [Member] Held-to-maturity Securities - Estimated Fair Value Debt Securities, Held-to-Maturity, Fair Value Other Proceeds from (Payment for) Other Financing Activity Allowances for doubtful accounts Accounts Receivable, Allowance for Credit Loss, Current Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Long-term taxes payable (Note 5) Accrued Income Taxes, Noncurrent Prepaid expenses and other Prepaid Expense and Other Assets, Current Derivative Instruments, Gain (Loss) [Line Items] Derivative Instruments, Gain (Loss) [Line Items] Deferred tax provision Deferred Income Tax Expense (Benefit) Selling, marketing and administrative expenses Selling, General and Administrative Expense Other Investment Not Readily Marketable, Name [Domain] Other Investment Not Readily Marketable, Name [Domain] Business Combination [Domain] Business Combination [Domain] Type of Restructuring [Domain] Type of Restructuring [Domain] Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Geographical Area, Revenue and Long-Lived Asset [Line Items] Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Geographical Area, Revenue and Long-Lived Asset [Line Items] Other than Temporary Impairment, Credit Losses Recognized in Earnings, Categories of Investments [Domain] Other than Temporary Impairment, Credit Losses Recognized in Earnings, Categories of Investments [Domain] Derivatives not designated as hedging instruments : Liabilities Foreign Currency Derivative Instruments Not Designated as Hedging Instruments, Liability at Fair Value Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Number of operating segments Number of Operating Segments Antidilutive securities excluded from computation of earnings per share, amount Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Goodwill Goodwill [Table Text Block] 3.550% Notes Due November 2044 3.550% Notes Due June 2044 [Member] 3.550% Notes Due June 2044 Entity Central Index Key Entity Central Index Key Less: accumulated depreciation Property, Plant, and Equipment, Accumulated Depreciation, Depletion, and Amortization Components of net periodic benefit cost Defined Benefit Plan, Net Periodic Benefit Cost (Credit) [Abstract] All Adjustments to Compensation All Adjustments to Compensation [Member] Corporate, Non-Segment Segment Reporting, Reconciling Item, Corporate Nonsegment [Member] Business Combination [Axis] Business Combination [Axis] Equity [Abstract] Equity [Abstract] Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member] Net cash flows from operating activities Cash Provided by (Used in) Operating Activity, Including Discontinued Operation Payments for legal settlements Payments for Legal Settlements Vision Vision [Member] Vision[Member] Legal proceedings Legal Matters and Contingencies [Text Block] Income Statement [Abstract] Income Statement [Abstract] Shareholders’ equity: Shareholders' equity: Equity, Attributable to Parent [Abstract] Document Transition Report Document Transition Report Fair Value Hierarchy and NAV [Axis] Fair Value, Hierarchy Fair Value Hierarchy and NAV [Axis] Acquired in-process research and development assets / related milestones (Note 10) Payments To Acquire In Process Research And Development Assets Payments To Acquire In Process Research And Development Assets Restructuring Plan [Domain] Restructuring Plan [Domain] Designated as Hedging Instrument Designated as Hedging Instrument [Member] Deferred taxes on income (Note 5) Deferred Income Tax Assets, Net Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Geographical Area, Revenue and Long-Lived Asset Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Geographical Area, Revenue and Long-Lived Asset [Table Text Block] GENERAL GENERAL [Member] GENERAL [Member] City Area Code City Area Code Disposal group, estimated term to complete Disposal Group, Including Discontinued Operation, Estimated Term To Complete Disposal Group, Including Discontinued Operation, Estimated Term To Complete Held-to-maturity Securities Held-to-Maturity Securities [Member] Accumulated Other Comprehensive Income (AOCI) Total Accumulated Other Comprehensive Income/(Loss) AOCI Attributable to Parent [Member] All Individuals All Individuals [Member] 3.50% Notes due 2048 3.500% Notes due 2048 [Member] 3.500% Notes due 2048 [Member] Cardiovascular Cardiovascular [Member] Cardiovascular[Member] Name Forgone Recovery, Individual Name Finished goods Inventory, Finished Goods, Net of Reserves Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Consideration transferred Business Combination, Consideration Transferred, Equity Interest TALVEY TALVEY [Member] TALVEY Carrying value, beginning of period Carrying value, end of period Marketable Securities, Noncurrent Statement [Line Items] Statement [Line Items] Restructuring charge percent to sales Restructuring charge percent to sales Restructuring charge percent to sales Total assets Assets Assets Entity [Domain] Entity [Domain] Schedule of Defined Benefit Plans Disclosures [Table] Defined Benefit Plan [Table] Business Combination [Abstract] Business Combination [Abstract] Derivatives designated as hedging instruments : Assets Derivative Instruments in Hedges, Assets, at Fair Value Amortization of prior service cost/‍(credit) Defined Benefit Plan, Amortization of Prior Service Cost (Credit) Operating Segments Operating Segments [Member] Interest expense, net of portion capitalized Interest Expense, Nonoperating SPINE & OTHER SPINE & OTHER [Member] SPINE & OTHER [Member] In-process research and development impairments Research And Development In Process1 Research And Development In Process1 Carrying value, beginning of period Carrying value, end of period Equity Securities without Readily Determinable Fair Value, Amount Liabilities assumed Business Combination, Recognized Liability Assumed, Liability Gain (loss) amortization during period Other Comprehensive (Income) Loss, Reclassification Adjustment from AOCI Pension and Other Postretirement Benefit Plans for Net Gain Loss, Net of Amortization, Net of Tax Other Comprehensive (Income) Loss, Reclassification Adjustment from AOCI Pension and Other Postretirement Benefit Plans for Net Gain Loss, Net of Amortization, Net of Tax Cost of products sold percent to sales Cost Of Goods Sold Percent To Sales Cost of goods sold percent to sales. Decrease/(Increase) in other current and non-current assets Increase (Decrease) in Other Operating Assets PEO PEO [Member] Net change Other Comprehensive Income (Loss), Net of Tax and Deconsolidation Other Comprehensive Income (Loss), Net of Tax and Deconsolidation Cash and Cash Equivalents [Domain] Cash and Cash Equivalents [Domain] Fair Value, by Balance Sheet Grouping, Disclosure Item Amounts Measurement Basis [Axis] Credit Support Agreement (CSA) Derivative Asset, Subject to Master Netting Arrangement, Liability Offset Marketable securities Marketable Securities, Current Other liabilities Other Liabilities, Noncurrent Immunology Immunology [Member] Immunology [Member] Goodwill (Note 3) Goodwill Beginning of Period Goodwill End of Period Goodwill Retirement Plan Type [Axis] Retirement Plan Type [Axis] Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Goodwill, related to acquisitions Goodwill, Acquired During Period Cash and Cash Equivalents Cash and Cash Equivalents, Policy [Policy Text Block] Other (income) expense, net Disposal Group, Including Discontinued Operation, Other Expense Derivatives designated as hedging instruments : Liabilities Derivative Instruments in Hedges, Liabilities, at Fair Value Due within one year Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One Intangible assets and Goodwill Intangible Asset, Excluding Goodwill, after Accumulated Amortization [Abstract] Retained Earnings and Additional Paid-in Capital Retained Earnings [Member] Money market funds Money Market Funds [Member] Equity, Fair Value Adjustment Equity, Fair Value Adjustment Gain/ (Loss) On Securities AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Parent [Member] Hedging exposure Derivative, Hedging Exposure, Term Derivative, Hedging Exposure, Term Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Unrealized holding gain (loss) arising during period OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax Award Timing Disclosures [Line Items] Foreign Currency Translation Accumulated Foreign Currency Adjustment Attributable to Parent [Member] Financial Liabilities not Measured at Fair Value Fair Value, by Balance Sheet Grouping [Table Text Block] Corporate debt securities(1) Corporate Debt Securities [Member] Credit support agreements activity, net Proceeds (Payments) from (to) Credit Support Agreements, Financing Activities Proceeds (Payments) from (to) Credit Support Agreements, Financing Activities Total net earnings per share - diluted (in dollars per share) Earnings Per Share, Diluted Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Table] Innovative Medicine Innovative Medicine [Member] Innovative Medicine Finite-Lived And Indefinite-Lived Intangible Assets [Line Items] Finite-Lived And Indefinite-Lived Intangible Assets [Line Items] Finite-Lived And Indefinite-Lived Intangible Assets [Line Items] Entity Current Reporting Status Entity Current Reporting Status Net cash (used for) from financing activities Cash Provided by (Used in) Financing Activity, Including Discontinued Operation Total Shareholder Return Amount Total Shareholder Return Amount 1.150% Notes due 2028 (750MM Euro 1.1354) 1.150% Notes Due 2028 [Member] 1.150% Notes Due 2028 [Member] Derivatives & hedges income (loss) Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax Cash Flow Hedging Cash Flow Hedging [Member] Litigation Case Type Litigation Case [Domain] Amortization expense of amortizable intangible assets Intangible Asset, Finite-Lived, Amortization Expense Intangible Asset, Finite-Lived [Line Items] Intangible Asset, Finite-Lived [Line Items] Adjustments to reconcile net earnings to cash flows from operating activities: Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract] EDURANT/rilpivirine EDURANT/rilpivirine [Member] EDURANT/rilpivirine [Member] OPSUMIT/OPSYNVI OPSUMIT/OPSYNVI [Member] OPSUMIT [Member] Assets acquired Business Combination, Recognized Asset Acquired, Asset Cash flows (used for) from financing activities Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract] Sales to customers (Note 9) Sales to customers Sales Revenue from Contract with Customer, Excluding Assessed Tax Property, plant and equipment, net Property, Plant, and Equipment, after Accumulated Depreciation, Depletion, and Amortization Sales by segment of business Segment Reporting, Revenue [Abstract] Interest cost Defined Benefit Plan, Interest Cost Reduction in effective income tax rate Effective Income Tax Rate Reconciliation, Increase (Decrease), Percent Effective Income Tax Rate Reconciliation, Increase (Decrease), Percent Financial Instruments [Domain] Financial Instruments [Domain] Schedule of Restructuring Reserve Schedule of Restructuring Reserve by Type of Cost [Table Text Block] Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract] Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract] 4.95% Notes due 2034 4.95% Notes Due 2034 [Member] 4.95% Notes Due 2034 IMBRUVICA IMBRUVICA [Member] IMBRUVICA [Member] Total Net Asset Derivative Asset Inventories Inventory Disclosure [Text Block] 3.350% Notes Due November 2036 3.350% Notes Due June 2036 [Member] 3.350% Notes Due June 2036 Intangible Asset, Finite-Lived, Class [Axis] Intangible Asset, Finite-Lived, Class [Axis] 2.25% Notes due 2050 2.250% Notes due 2050 [Member] 2.250% Notes due 2050 Equity Awards Adjustments, Footnote Equity Awards Adjustments, Footnote [Text Block] Intangible assets and goodwill Intangible Asset and Goodwill [Text Block] 3.350% Notes Due February 2037 3.350% Notes Due February 2037 [Member] 3.350% Notes Due February 2037 2.700% Notes Due February 2029 2.700% Notes Due February 2029 [Member] 2.700% Notes Due February 2029 Underlying Securities Award Underlying Securities Amount Estimated Fair Value Estimate of Fair Value Measurement [Member] Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table] Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table] Subsegments [Domain] Subsegments [Domain] Debt Securities, Held-to-maturity [Abstract] Debt Securities, Held-to-Maturity, Amortized Cost, before Allowance for Credit Loss [Abstract] Supplier finance program, payment timing, period Supplier Finance Program, Payment Timing, Period 4.85% Notes Due 2032 4.85% Notes Due 2032 [Member] 4.85% Notes Due 2032 Amount of gain or (loss) recognized in AOCI Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, after Tax Subsegments [Axis] Subsegments [Axis] Raw materials and supplies Inventory, Raw Materials and Supplies, Net of Reserves Other (including capitalized licenses and milestones) Payment for (Proceeds from) Other Investing Activity Increase in inventories Increase (Decrease) in Inventories Segment Reporting [Table] Segment Reporting [Table] Schedule of Finite-Lived And Indefinite-Lived Intangible Assets By Major Class [Table] Schedule of Finite-Lived And Indefinite-Lived Intangible Assets By Major Class [Table] Schedule of Finite-Lived And Indefinite-Lived Intangible Assets By Major Class [Table] Effective income tax rate reconciliation, tax settlement, percent Effective Income Tax Rate Reconciliation, Tax Settlement, Percent Sales by geographic area Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Geographical Area [Abstract] Cash Cash [Member] Summary of Activity Related to Equity Investments Schedule of Available-for-Sale Securities Reconciliation [Table Text Block] Weighted average interest rate on non-current debt Long-Term Debt, Weighted Average Interest Rate, at Point in Time Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] All Trading Arrangements All Trading Arrangements [Member] Beginning Balance Ending Balance Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value Gain/(Loss) Recognized In Income on Derivative Derivative, Gain (Loss) on Derivative, Net Other Performance Measure, Amount Other Performance Measure, Amount Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Current Fiscal Year End Date Current Fiscal Year End Date 2.90% Notes due 2028 2.900% Notes due 2028 [Member] 2.900% Notes due 2028 [Member] International UNITED STATES Exports [Member] UNITED STATES Exports [Member] Held-to-maturity Securities - Carrying Amount Debt Securities, Held-to-Maturity, Amortized Cost, before Allowance for Credit Loss Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Derivative [Line Items] Derivative [Line Items] Restructuring estimated cost Restructuring and Related Cost, Expected Cost Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member] Entity File Number Entity File Number Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Service cost Defined Benefit Plan, Service Cost Royalty Pharma plc. Royalty Pharma plc. [Member] Royalty Pharma plc. Equity Securities Equity Securities [Member] Asset write-downs Asset, Impairment Loss Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Gross Profit Percent To Sales Gross Profit Percent To Sales Gross profit percent to sales. Common stock, shares issued (in shares) Common Stock, Shares, Issued Measure: Measure [Axis] Entity Information [Line Items] Entity Information [Line Items] 4.95% Notes due 2033 4.95% Debentures due 2033 [Member] 4.95% Debentures due 2033 [Member] Treasury stock (in shares) Treasury Stock, Common, Shares KNEES KNEES [Member] KNEES [Member] Selling marketing and administrative expenses percent to sales Selling General And Administrative Expense Percent To Sales Selling general and administrative expense percent to sales. Accumulated other comprehensive income Comprehensive Income (Loss) Note [Text Block] Equity Components [Axis] Equity Components [Axis] Increase in accounts receivable Increase (Decrease) in Accounts Receivable Product and Service [Domain] Product and Service [Domain] Entity Interactive Data Current Entity Interactive Data Current Available-for-sale Securities Available-for-Sale Securities [Member] Deferred taxes on income (Note 5) Deferred Income Tax Liabilities, Net Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] CARVYKTI CARVYKTI [Member] CARVYKTI Due after one year through five years Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five Fair Value Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Fair Value [Abstract] Entity Small Business Entity Small Business Comprehensive income Comprehensive Income (Loss), Net of Tax, Attributable to Parent Termination Date Trading Arrangement Termination Date Disposal Group, Disposed of Other than by Sale, Not Discontinued Operation, Spinoff Disposal Group, Disposed of Other than by Sale, Not Discontinued Operation, Spinoff [Member] Payments Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements Loss contingency accrual, payment percentage Loss Contingency Accrual, Percentage Loss Contingency Accrual, Percentage Amortizable intangibles asset Business Combination, Recognized Asset Acquired, Identifiable Intangible Asset, Finite-Lived Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Net change Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Other assets Non Current Other Assets Other Assets, Noncurrent Document Type Document Type Acquisitions, net of cash acquired (Note 10) Payments to acquire businesses Payments to Acquire Businesses, Net of Cash Acquired Foreign currency translation adjustment income (loss) Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax Accrued liabilities Accrued Liabilities, Current Fair Value as of Grant Date Award Grant Date Fair Value SPRAVATO SPRAVATO [Member] SPRAVATO Charges for acquired in-process research and development assets In-Process Research And Development Charge In-Process Research And Development Charge Schedule of Goodwill [Table] Goodwill [Table] 3.40% Notes due 2038 3.400% Notes due 2038 [Member] 3.400% Notes due 2038 [Member] Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Arrangement Duration Trading Arrangement Duration Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Proceeds from long-term debt, net of issuance costs Proceeds from Issuance of Long-Term Debt Local Phone Number Local Phone Number Other Benefit Plans Other Postretirement Benefits Plan [Member] Consolidation Items [Axis] Consolidation Items [Axis] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Entity Registrant Name Entity Registrant Name Net Investment Hedging Net Investment Hedging [Member] Earnings before provision for taxes on income Earnings before provision for taxes on income Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] 3.20% Notes due 2032 (700MM Euro 1.0721) 3.20% Notes Due 2032 [Member] 3.20% Notes Due 2032 Commitments and Contingencies (Note 11) Commitments and Contingencies Finite-lived intangible assets, gross Intangible Asset, Finite-Lived, before Accumulated Amortization Property, plant and equipment at cost Property, Plant, and Equipment, before Accumulated Depreciation, Depletion, and Amortization Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] 2030 Intangible Asset, Finite-Lived, Estimated Amortization Expense, Year Four Decrease in accounts payable and accrued liabilities Increase (Decrease) in Accounts Payable and Accrued Liabilities Income Tax Contingency [Table] Income Tax Contingency [Table] Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Executive Category: Executive Category [Axis] Other Notes Due Period Fifteen Member Notes due period fifteen. Total debt securities Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Fair Value Goodwill [Roll Forward] Goodwill [Roll Forward] Liabilities and shareholders’ equity Liabilities and Equity [Abstract] Intangible Asset, Finite-Lived, Class [Domain] Intangible Asset, Finite-Lived, Class [Domain] Sales By Segment Of Business Sales By Segment Of Business [Table Text Block] Sales by segment of business. Inventories (Note 2) Total inventories Inventory, Net All Award Types Award Type [Domain] Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Fair value measurements Fair Value Disclosures [Text Block] Significant unobservable inputs Level 3 Fair Value, Inputs, Level 3 [Member] Reclassifications to earnings Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax 2027 Intangible Asset, Finite-Lived, Estimated Amortization Expense, Year One PEO Name PEO Name Geographical [Axis] Geographical [Axis] Gain/ (Loss) On Derivatives & Hedges Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member] 3.73% Notes due 2046 3.70% Notes due 2046 [Member] 3.70% Notes due 2046 [Member] Financial Liabilities Financial Instruments, Financial Liabilities, Balance Sheet Groupings [Abstract] Total cash, cash equivalents and current marketable securities, Carrying Amount Cash, Cash Equivalents, and Short-Term Investments Less: Expense not allocated to segments Segment Reporting, Other Segment Item, Amount Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Foreign currency translation Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss), before Reclassification and Tax Entity Tax Identification Number Entity Tax Identification Number Legal Entity [Axis] Legal Entity [Axis] Unrealized gain (loss) arising during period Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax Other Oncology Other Oncology [Member] Other Oncology [Member] Repurchase of common stock (including excise tax) Treasury Stock, Value, Acquired, Cost Method Cash and cash equivalents, beginning of period Cash and cash equivalents, end of period Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation Employee compensation and stock option plans Stock Issued During Period, Value, Treasury Stock Reissued Schedule of Finite-Lived Intangible Assets by Major Class [Table] Intangible Asset, Finite-Lived [Table] Repurchase of common stock (including excise tax) Treasury Stock, Value, Acquired, Cost Method, Net Of Excise Tax Treasury Stock, Value, Acquired, Cost Method, Net Of Excise Tax Asset acquired, identifiable intangible asset, indefinite-lived Business Combination, Recognized Asset Acquired, Identifiable Intangible Asset, Indefinite-Lived Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] ERLEADA ERLEADA [Member] ERLEADA 5.00% Notes due 2035 5.00% Notes due 2035 [Member] 5.00% Notes due 2035 Additions Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Non-NEOs Non-NEOs [Member] Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member] Patents And Trademarks Patents And Trademarks [Member] Patents And Trademarks [Member] Debt Instrument [Axis] Debt Instrument [Axis] MedTech Surgery Franchise MedTech Surgery Franchise [Member] MedTech Surgery Franchise Stock based compensation Share-Based Payment Arrangement, Noncash Expense MedTech MEDTECH MedTech [Member] Medical Devices [Member] 3.625% Notes due 2037 3.625% Notes due 2037 [Member] 3.625% Notes due 2037 [Member] 2028 Intangible Asset, Finite-Lived, Estimated Amortization Expense, Year Two Disposal Group Name [Axis] Disposal Group Name [Axis] OTHER IMMUNOLOGY Other Immunology [Member] Other Immunology [Member] Debt Securities, Available-for-sale and Held-to-maturity [Abstract] Debt Securities, Available-for-Sale and Held-to-Maturity, after Allowance for Credit Loss [Abstract] Summary of Inventories Schedule of Inventory, Current [Table Text Block] Due after five years through ten years Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10 Financial Assets and Liabilities at Fair Value Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block] Total net earnings per share - basic (in dollars per share) Earnings Per Share, Basic Tecvayli Tecvayli [Member] Tecvayli Repurchase of common stock Payments for Repurchase of Common Stock Total current assets Assets, Current Statistical Measurement [Axis] Statistical Measurement [Axis] Insider Trading Arrangements [Line Items] Summary of Derivative Activity Derivative Instruments, Gain (Loss) [Table Text Block] Long-term debt (Note 4) Non-Current Debt Long-Term Debt, Excluding Current Maturities Other Investment Not Readily Marketable [Line Items] Other Investment Not Readily Marketable [Line Items] Time deposits(1) Bank Time Deposits [Member] Other Investment Not Readily Marketable [Axis] Other Investment Not Readily Marketable [Axis] Award Type Award Type [Axis] Interest Rate Contract Interest Rate Contract [Member] Cumulative Amount of Fair Value Hedging Gain/ (Loss) Included in the Carrying Amount of the Hedged Liability Hedged Liability, Fair Value Hedge, Cumulative Increase (Decrease) Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Accounts receivable, trade, less allowances $171 (2025, $183) Accounts Receivable, after Allowance for Credit Loss, Current Retained earnings and Additional paid-in capital Retained Earnings (Accumulated Deficit) Gain/(Loss) Recognized In Accumulated OCI Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments and Tax Restructuring and Related Activities [Abstract] Restructuring and Related Activities [Abstract] Product and Service [Axis] Product and Service [Axis] Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member] Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Retirement Plans Pension Plan [Member] Common Stock, Par Value $1.00 Common Stock Issued Amount Common Stock [Member] Other commitment, maximum funds to receive Other Commitment, Maximum Funds To Receive Other Commitment, Maximum Funds To Receive Available-for-sale Securities Available-for-sale Securities - Estimated Fair Value Debt Securities, Available-for-Sale Effect of Change in Accounting Estimate, Type [Axis] Effect of Change in Accounting Estimate, Type [Axis] Fair Value Measurement [Domain] Fair Value Measurement [Domain] Contingent consideration Business Combination, Contingent Consideration, Liability Supplier finance program, obligation Supplier Finance Program, Obligation, Current Litigation expense Litigation Settlement, Fee Expense Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Cover [Abstract] Cover [Abstract] Interest expense, net of portion capitalized percent to sales Interest Expense Percent To Sales Interest expense percent to sales. International Non-US [Member] Proceeds from the exercise of stock options/employee withholding tax on stock awards, net Proceeds From The Exercise Of Stock Options And Excess Tax Benefits Proceeds From The Exercise Of Stock Options And Excess Tax Benefits Derivative Contract [Domain] Derivative Contract [Domain] Derivatives & hedges: Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent [Abstract] Equity Awards Adjustments Equity Awards Adjustments [Member] Hedging Relationship [Domain] Hedging Relationship [Domain] Total liabilities and shareholders’ equity Liabilities and Equity Employee Stock Option Share-Based Payment Arrangement, Option [Member] Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Geographical Area, Revenue and Long-Lived Asset [Table] Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Geographical Area, Revenue and Long-Lived Asset [Table] Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] General Corporate General Corporate [Member] General corporate member. Statement, Business Segments Segments [Axis] Segments [Axis] Decrease in other current and non-current liabilities Increase (Decrease) in Other Operating Liabilities Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Asset Class [Axis] Asset Class [Axis] Restructuring (Note 12) Restructuring charges Restructuring Charges 2.45% Notes due 2060 2.450% Notes due 2060 [Member] 2.450% Notes due 2060 Inventory Disclosure [Abstract] Inventory Disclosure [Abstract] Tabular List, Table Tabular List [Table Text Block] 4.85% Notes due 2041 4.85% Notes due 2041 [Member] 4.85% Notes due 2041 [Member] Intangible assets with definite lives: Intangible Asset, Finite-Lived, after Accumulated Amortization [Abstract] Other (income) expense, net Other (income) expense, net Other Nonoperating Income (Expense) Repayment of long-term debt Repayments of Senior Debt 2029 Intangible Asset, Finite-Lived, Estimated Amortization Expense, Year Three 2026 Intangible Asset, Finite-Lived, Estimated Amortization Expense, Remainder of Fiscal Year Name Awards Close in Time to MNPI Disclosures, Individual Name Other Other [Member] Other [Member] Purchases of investments Payments to Acquire Investments Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member] 3.050% Notes Due February 2033 3.050% Notes Due February 2033 [Member] 3.050% Notes Due February 2033 3.587% Notes due 2036 3.587% Notes Due 2036 [Member] 3.587% Notes Due 2036 Derivatives, Fair Value [Line Items] Derivatives, Fair Value [Line Items] TRAUMA TRAUMA [Member] TRAUMA [Member] Adjustment to Compensation: Adjustment to Compensation [Axis] Change in Accounting Method Accounted for as Change in Estimate Change in Accounting Method Accounted for as Change in Estimate [Member] Hedging Designation [Domain] Hedging Designation [Domain] Class of Stock [Domain] Class of Stock [Domain] Restructuring Cost and Reserve [Line Items] Restructuring Cost and Reserve [Line Items] Oncology Oncology [Member] Oncology [Member] Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Curtailments and settlements Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement and Curtailment Hedging Designation [Axis] Hedging Designation [Axis] In-process research and development In Process Research and Development [Member] Debt Security Category [Axis] Debt Security Category [Axis] Restructuring Restructuring and Related Activities Disclosure [Text Block] Net earnings from continuing operations percent of sales Income (Loss) From Continuing Operations, Net Of Tax, Attributable To Parent, Percent Of Sales Income (Loss) From Continuing Operations, Net Of Tax, Attributable To Parent, Percent Of Sales Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Research and development expense percent to sales Research And Development Expense Excluding Acquired In Process Cost Percent To Sales Research and development expense excluding acquired in process cost percent to sales. Name Measure Name Income taxes Income Tax Disclosure [Text Block] Total cash, cash equivalents and current marketable securities, Estimated Fair Value Cash, Cash Equivalents, And Short-Term Investments, Estimated Fair Value Cash, Cash Equivalents, and Short-term Investments, Estimated Fair Value Schedule of Cash and Cash Equivalents [Table] Cash and Cash Equivalent [Table] Accounts payable Accounts Payable, Current Pay vs Performance Disclosure [Line Items] Fair Value Hierarchy and NAV [Domain] Fair Value, Measurements, Fair Value Hierarchy Fair Value Hierarchy and NAV [Domain] 5.95% Notes due 2037 5.95% Notes due 2037 [Member] 5.95% Notes due 2037 [Member] Schedule of Derivative Financial Instruments and Classification on Consolidated Balance Sheet Schedule of Derivatives Instruments Statements of Financial Performance and Financial Position, Location [Table Text Block] Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Business acquisition cost Business Combination, Consideration Transferred Retirement Plan Type [Domain] Retirement Plan Type [Domain] Entity Filer Category Entity Filer Category Indefinite-lived Intangible Assets [Axis] Intangible Asset, Indefinite-Lived, Class [Axis] Repayment of short-term debt, net Repayments of Short-Term Debt Name Trading Arrangement, Individual Name Cash and cash equivalents (Note 4) Cash and Cash Equivalents Cash and Cash Equivalent Retirement Plan Sponsor Location [Axis] Retirement Plan Sponsor Location [Axis] Employee benefit plans: Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent [Abstract] 2.10% Notes due 2040 2.10% Notes due 2040 [Member] 2.10% Notes due 2040 CONCERTA/Methylphenidate CONCERTA/Methylphenidate [Member] CONCERTA/Methylphenidate [Member] STELARA Stelara [Member] Stelara [Member] SURGICAL SURGICAL [Member] SURGICAL [Member] Total PH, ID, CVM Total PH, ID, CVM [Member] Total PH, ID, CVM Company Selected Measure Amount Company Selected Measure Amount Not Designated as Hedging Instrument Not Designated as Hedging Instrument [Member] Depreciation and amortization of property and intangibles Depreciation and Amortization Depreciation, Depletion and Amortization Orthopaedics Orthopaedics [Member] Orthopaedics [Member] Retirement Plan Sponsor Location [Domain] Retirement Plan Sponsor Location [Domain] Infectious Diseases Infectious Diseases [Member] Infectious Diseases [Member] Non-Current Debt Long-Term Debt, Excluding Current Maturities [Abstract] Share price (in dollars per share) Business Combination, Price Per Share Pulmonary Hypertension Pulmonary Hypertension [Member] Pulmonary Hypertension [Member] Current assets: Assets, Current [Abstract] Foreign exchange rate Foreign Currency Exchange Rate, Translation Total Net Liabilities Derivative Liability ELECTROPHYSIOLOGY Electrophysiology [Member] Electrophysiology Non-PEO NEO Non-PEO NEO [Member] Entity Address, Address Line One Entity Address, Address Line One Provision for taxes on income (Note 5) Income Tax Expense (Benefit) Fair Value Hedging Fair Value Hedging [Member] Cost of products sold Cost of Product and Service Sold Reversal of fee expense Litigation Settlement, Reversal Of Fee Expense Litigation Settlement, Reversal Of Fee Expense Award Timing Method Award Timing Method [Text Block] Increase in cash and cash equivalents Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation Scenario, Forecast Forecast [Member] Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] 4.90% Notes due 2031 4.90% Notes Due 2031 [Member] 4.90% Notes Due 2031 Research and development expense Research and Development Expense (Excluding Acquired in Process Cost) Recognized actuarial (gains)/losses Defined Benefit Plan, Amortization of Gain (Loss) Summary of Significant Accounting Policies Accounting Standards Update and Change in Accounting Principle [Text Block] Percent Change (as a percent) Percentage Change In Sales By Segment Of Business Percentage change in sales by segment of business. Net earnings Net earnings Net earnings Net Income (Loss) Attributable to Parent Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Statement [Table] Statement [Table] 4.70% Notes due 2030 4.70% Notes due 2030 [Member] 4.70% Notes due 2030 Restatement Determination Date: Restatement Determination Date [Axis] Asia-Pacific, Africa Asia-Pacific, Africa [Member] Asia-Pacific, Africa [Member] Components of Accumulated Other Comprehensive Income Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Interest income Investment Income, Interest UPTRAVI UPTRAVI [Member] UPTRAVI [Member] Total Gross Assets Derivative Asset, Subject to Master Netting Arrangement, before Offset OTHER INFECTIOUS DISEASES Other Infectious Diseases [Member] Other Infectious Diseases [Member] Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Axis] Proceeds from short-term debt, net Proceeds from Short-Term Debt Segments Total Segments Total [Member] Segments Total Collateral already posted, aggregate fair value Collateral Already Posted, Aggregate Fair Value Pension Benefits Adjustments, Footnote Pension Benefits Adjustments, Footnote [Text Block]